{
    "medicine_id": "31f2c88ab5ec81de7c576379cced23d0b1def55c",
    "platform_id": "DB11842",
    "metadata": {
        "name": "Giapreza 2 5 mg 1mL Injection",
        "composition": "2 5 mg 1mL Angiotensin II",
        "clinical_particulars": {
            "therapeutic_indications": "Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock FDA Label",
            "contraindications": {
                "disease": "Overdose with angiotensin II would be expected to result in hypertension necessitating close monitoring and supportive care FDA Label Effects are also expected to be brief as the half life of angiotensin II is less than one minute FDA Label In the ATHOS 3 clinical study there was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients The major imbalance was in deep venous thromboses which prompts the potential need to use concurrent venous thromboembolism VTE prohphylaxis FDA Label Adverse effects of noticeable potential 10 include thromboembolic events ie like deep vein thrombosis including arterial and venous thrombotic events thrombocytopenia tachycardia and fungal infection Effects whose potential are 10 include delirium acidosis hyperglycemia peripheral ischemia FDA Label Concomitant use of angiotensin converting enzymes ACE inhibitors may increase the response of angiotensin II FDA Label Concomitant use of angiotensin II blockers ARBs may decrease the response to angiotensin II FDA Label There are no formal data regarding the safe use of angiotensin II in pregnant women However septic or other distributive shock is a medical emergency that can be fatal if left untreated Delaying treatment in pregnant women with hypotension associated with septic or otherdistributive shock is likely to increase the risk of maternal and fetal morbidity and mortality FDA Label There is no formal data regarding whether or not angiotensin II may become present in human milk and there is no data available on the effects of angiotensin II on the breastfed child or the effects on milk production FDA Label The safety and efficacy of angiotensin II in pediatric patients has not yet been established FDA Label There is no difference in the safety or efficacy between patients less than 65 years old and those 65 years or older when treated with angiotensin II FDA Label There is no difference in pharmacokinetics between male and female patients FDA Label The pharmacokinetics of angiotensin II are not expected to be influenced by renal impairment or hepatic impairment FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Angiotensin II is a naturally occurring peptide hormone of the renin angiotensin aldosterone system RAAS that has the capacity to cause vasoconstriction and an increase in blood pressure in the human body FDA Label In the RAAS juxtaglomerular cells of the renal afferent arteriole synthesize the proteolytic enzyme renin Although stored in an inactive form called pro renin decreases in arterial blood pressure or extracellular fluid volume depletion can cause various enzymatic reactions to release active renin into the systemic circulation and surrounding tissues Such renin release allows for the production of the alpha 2 globulin angiotensinogen predominantly in the liver and to some extent the kidneys and other organs A31494 Angiotensin I itself a decapeptide with weak biological activity is produced from angiotensinogen and then quickly converted to angiotensin II by angiotensin converting enzymes ACE Consequently angiotensin II demonstrates its strong vasopressor activity when it is rapidly degraded by aminopeptidases A and M into further entities like angiotensin III and angiotensin IV respectively Such species like angiotensin III can then bind and interact with specific G protein coupled receptors like angiotensin receptor 1 or AT 1 A31494 where strong vasoconstricson can occur A31494 Furthermore in the ATHOS 3 clinical trial for the 114 70 patient subjects in the angiotensin II arm who reached the target mean arterial pressure MAP at Hour 3 the median time to reach the target MAP endpoint was approximately 5 minutes The angiotensin II was titrated to effect for each individual patient FDA Label",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB13967",
                        "description": "The risk or severity of hypotension can be increased when Patent Blue is combined with Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB00024",
                        "description": "Thyrotropin alfa may increase the vasoconstricting activities of Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB00279",
                        "description": "Liothyronine may increase the vasoconstricting activities of Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB00451",
                        "description": "Levothyroxine may increase the vasoconstricting activities of Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB01583",
                        "description": "Liotrix may increase the vasoconstricting activities of Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB03604",
                        "description": "Tiratricol may increase the vasoconstricting activities of Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB09100",
                        "description": "Thyroid porcine may increase the vasoconstricting activities of Angiotensin II"
                    },
                    {
                        "drugbank-id": "DB00281",
                        "description": "The risk or severity of hypertension can be increased when Angiotensin II is combined with Lidocaine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}